Vir Biotechnology Inc
For the period ended Dec 31, 2023. Filed Feb 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 26, 2024
VIR$13.65+11.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
| Audited Consolidated Financial Statements | Page |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | 112 |
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | 114 |
| Consolidated Statements of Operations for the years ended December 31, 2023, 2022 and 2021 | 115 |
| Consolidated Statements of Comprehensive (Loss) Income for the years ended December 31, 2023, 2022 and 2021 | 116 |
| Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2023, 2022 and 2021 | 117 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2023, 2022 and 2021 | 118 |
| Notes to Consolidated Financial Statements | 120 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.